earnings
confidence high
sentiment negative
materiality 0.60
Azitra Q2 net loss $2.9M; cash $1.0M; ATR-12 Phase 1b shows safety
Azitra, Inc.
2025-Q2 EPS
reported -$0.40
vs consensus -$1.43
▲ beat
(+72.0%)
- Net loss of $2.9M for Q2 2025, up from $2.6M in Q2 2024; R&D spend $1.4M, G&A $1.5M.
- Cash and equivalents $1.0M as of June 30, 2025; entered $20M equity line with Alumni Capital LP.
- ATR-12 Phase 1b in Netherton syndrome: 50% enrolled, promising safety in first 5 patients.
- ATR-04 Phase 1/2 for EGFRi rash: design presented at ASCO; first patient dosing expected Q3 2025.
- Anticipated topline data for ATR-12 in Q1 2026.
item 2.02item 9.01